Literature DB >> 7381512

Anti-ganglioside antibodies in multiple sclerosis.

R Arnon, E Crisp, R Kelley, G W Ellison, L W Myers, W W Tourtellotte.   

Abstract

Serological activity against several purified brain gangliosides has been demonstrated in sera of a proportion of multiple sclerosis patients, but not in normal individuals. The activity was determined by the capacity of the sera to bring about complement-dependent lysis of liposomes containing the respective ganglioside in their lipid bilayer. An apparent correlation is indicated between the severity of the disease and the extent of liposome lysis. Cerebrospinal fluid of the patients did not induce lysis, probably due to low antibody concentration.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7381512     DOI: 10.1016/0022-510x(80)90076-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  19 in total

1.  Pathogenesis of multiple sclerosis.

Authors:  R A Hughes
Journal:  J R Soc Med       Date:  1992-07       Impact factor: 5.344

2.  Neuropsychiatric manifestations of systemic lupus erythematosus: the value of anticardiolipin, antigangliosides and antigalactocerebrosides antibodies.

Authors:  L T Costallat; R M de Oliveira; M B Santiago; W Cossermelli; A M Samara
Journal:  Clin Rheumatol       Date:  1990-12       Impact factor: 2.980

3.  The role of the thymus in multiple sclerosis.

Authors:  V D'Andrea; G Meco; F Corvese; P F Baselice; V Ambrogi
Journal:  Ital J Neurol Sci       Date:  1989-02

4.  Serum ganglioside patterns in multiple sclerosis.

Authors:  E Zaprianova; D Deleva; P Ilinov; E Sultanov; A Filchev; L Christova; B Sultanov
Journal:  Neurochem Res       Date:  2001-02       Impact factor: 3.996

Review 5.  Illuminating vitamin D effects on B cells--the multiple sclerosis perspective.

Authors:  Linda Rolf; Anne-Hilde Muris; Raymond Hupperts; Jan Damoiseaux
Journal:  Immunology       Date:  2016-02-02       Impact factor: 7.397

6.  Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

Authors:  P O Livingston; E J Natoli; M J Calves; E Stockert; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

7.  Chronic relapsing experimental allergic encephalomyelitis: its value as an experimental model for multiple sclerosis.

Authors:  H Lassmann
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

8.  Cerebrospinal fluid antiganglioside antibodies in patients with AIDS.

Authors:  M Sorice; T Griggi; A Circella; G Nicodemo; M Ciardi; C M Mastroianni; L Lenti; F Sorice
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

9.  Ganglioside GM1, a molecular target for immunological and toxic attacks: similarity of neuropathological lesions induced by ganglioside-antiserum and cholera toxin.

Authors:  B Schwerer; H Lassmann; K Kitz; H Bernheimer
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

10.  Autoantibodies against Forssman glycolipids in Graves' disease and Hashimoto's thyroiditis.

Authors:  T Ariga; T Yoshida; T Mimori; R K Yu
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.